In an interconnected world, global health is not just a scientific aspiration but an economic one. As supply shortages brought on by factory shutdowns in China demonstrate, a disease outbreak in one part of the world has ramifications on the other side of the globe. Johanna Benesty, who leads BCG’s global health work, talks about the opportunities for pharmaceutical and other health care companies in serving underserved populations in lower- and middle-income countries and elsewhere. Price is not the only barrier. Treatments may need to be redesigned to meet the realities of these countries rather than the wealthy countries where they were developed.